OMER → $30.00 by Sep 22, 2026.

This isn’t financial advice, simply my own opinion, so do your own DD TLDR: OMER is trading around $973 million market cap. Their drug Yartemlea alone could give the company over a $5 billion market cap. Considering their $2.1 billion deal with NOVO for another drug in their pipeline, Zaltenibart, I think OMER is currently undervalued. I think OMER will be trading around $30 per share by the end of summer. My bullish estimate is $40+ (with EMA approval, EU …